Partner
Joined: 2016
and access,
Edward Chan joined 1315 Capital in 2016 after spending 5 years at NaviMed Capital. Prior to joining NaviMed Capital, Edward was part of the healthcare investment team at Siemens Venture Capital. Edward also held an investment role at SAC Capital and a marketing role at Medtronic Cardiovascular. Edward started his career developing and commercializing a molecular diagnostic product at a venture backed company. Edward has served on the board or as a board observer at the following companies: Genoptix (acquired by NeoGenomics), Centurion Service Group (acquired by TRIMEDX), CenterPointe Behavioral Health System (acquired by Acadia Healthcare), and Greenbrook TMS. He currently serves on the board of Homestead Smart Health Plans and Interpace Biosciences. Edward received a BSc in Biomedical Engineering from Johns Hopkins University and an MBA in Healthcare Management and Finance from the Wharton School at the University of Pennsylvania.
The Wharton School of the University of Pennsylvania , Pennsylvania,
1 of 523
Johns Hopkins University , Maryland,
1 of 26